Errors in the use of strong opioids have led to the elimination of control of optimal illnesses among Asian oncology patients undergoing chemotherapy and radiotherapy on a horizontal survey conducted at the Sarawak General Hospital in Malaysia.
In the ESMO Asia 2018 Congress, a total of 133 patients with severe tumors at all stages of treatment with strong opioids will be able to evaluate the effects of daily pains on the pain by visual analogue scale (VAS) from 0 to 10 and completion of short-term pain management – short form (BPI-sf).
The researchers also explored the types of strong opioids, using barriers to effective management of malignant neoplasms; the results were assessed by social determinants, such as the ethnic group, religion, and the level of education.
On the whole, 62% of respondents had good pain control (pain symptoms)
In patients with higher levels of education, major obstacles to the control of the disease have been identified, suggesting that the use of opioids in social media is widespread. The fear of exposure to opioids is common in the Malay community, followed by Chinese and tribal groups. "These differences can indicate some inequality in achieving optimal cancer care in the country, but many socio-economic factors can play an important role in the opiates use, so we need further investigation," Dr. Woon explained.
Despite the availability or availability of opioids in some countries, according to Professor Sumitra Thongprasert, professor of Sumitra Thongprasert, co-chair of ESMO Asia 2018 State Policy, Professor of Chiang Mai Hospital in Thailand. "Religious and other cultural issues can partially explain the optimal use of opioid analgesics and a number of factors are estimated, including the benefits of these drugs from health care providers," he explained. "Most importantly, the achievement of opioids and state restrictions on the total amount of patients per day can have a significant impact on the availability and use of oncologic patients."
For the first time in 2013, the OOP's Political Initiatives (GOPI) conducted by MNE with other international partners identified the issues of accessibility, cost and regulatory barriers to the selection and dissemination of opioid analgesics in low and medium-sized countries. Except for South Korea and Japan, all 20 Asian researchers have found that opioid availability is low and excessive regulation of opioid recipients in the Asia-Pacific region limits or destroys access to pain relief procedures. The result of this initiative has highlighted the need for improved knowledge about palliative care among clinical physicians in Asian countries.
"Though nowadays, critical medicines, such as opiates, targeted drugs, and immunotherapy may be available in Asia, the problem of access to affordable cancer treatment will not be resolved in the future," continued Thongprasert. "In some countries in Asia / Asia / Pacific countries, expensive medicines can not be provided to local communities, and cancer patients can be the main cause of high quality of medicines in countries where patients are paying for the treatment of oncological diseases.
Dr. Nathan Cherney, a professor at the Shaare Zedek Medical Center in Israel, said that, as a co-ordinator for the global opioid policy initiative for ESMO, "according to the results published in 2013, WHO, International Anti-Drug Administration and ESMO, as well as 20 international and national palliative care and oncological societies, opioid analgesics that serve as the basis for the treatment of oncological diseases and opioids l indicator and should be transformed into a priority of public health. "
The strategy for improving availability and accessibility of oncologic drugs in LMIC will be discussed in thought-provoking discussions at the ESMO Asia 2018 Congress in Singapore. "Decrease in oncological medication costs may require time, assessment of other potential strategies such as setting different prices according to economic status, pharmaceutical companies providing access to patients or transfer of LMIC technology for the production of their medicinal products; availability of reliable and genetic medicines for medicinal preparations and mandatory licensing of anti-cancer drugs, the rate of development of new medicines in these countries, limited access to research projects, lack of new technologies. Thongprasert added.
In recent years, the global commitment to providing access to antibacterial drugs has been rising and, according to ESMO President Josep Tabernero, cooperation between different stakeholders will help better manage Asia-Pacific countries, with the goal of improving access to essential medicines, vaccines, diagnostics, and medical devices.
"In general, there is a need to prioritize limited resources to adequate clinical preferences and joint efforts have led to new tools and approaches that can make important steps in addressing policy issues in the LMICs. One of them is the ESMO value of the Clinical Benefits (ESMO-MCBS) , 7), which help Governments review and adjust their national drug list to ensure that patients are the most economical to the highest value.
By contributing to the training and upgrading of oncology specialists in the Asia-Pacific region, the annual ESMO Asian Congress, launched in 2014, provides a space for knowledge sharing and discusses and discusses key issues of oncology development. making real and necessary changes, "concluded the president of ESMO.
The quality of cancer treatment is not just anti-cancer drugs
Annotation 439P – Daniel Lee, from November 24 to 6 pm, suggests that Daniel Lee's "Controlling Opposition by the strong opioids and their compatibility with the multicultural backdrop of opioids." : 00 (SGT) at the exhibition grounds. Anniversaries of oncology, 29 volumes, 2018 Appendix 9, DOI: 10.1093 / annonc / mdy426